Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493883 · ClinicalTrials.gov registry record · Phase 1
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
A Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms, sponsored by Southwestern Regional Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT00493883 is a Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms that has completed, run by Southwestern Regional Medical Center. The registered enrollment target is 81 participants, below the 610-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00493883, a Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms, has completed, sponsored by Southwestern Regional Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity. The study has the following objectives: * Provide supervised access to treatment with TheraSphere to eligible patients with primary and metastatic cancer to the liver. * Evaluate patient experience and toxicities associated with TheraSphere treatment * Evaluate predisposing factors that may influence results and toxicity
Conditions Studied
Interventions
- DEVICE yttrium Y 90 microspheres (TheraSphere®)
Study Locations (1)
Oklahoma
- Cancer Treatment Centers of America at Southwestern Regional Medical Center - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493883
The ClinicalTrials.gov registry entry for NCT00493883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 610-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (87% lower). The listed sponsor is Southwestern Regional Medical Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which yttrium Y 90 microspheres (TheraSphere®) is the first listed.
NCT00493883 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00493883 about?
NCT00493883 is a clinical study titled "Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors". The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity. The study has the following objectives: * Provide supervised access to treatment with TheraSph...
What is the current status of trial NCT00493883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2006-12. Estimated completion is 2011-12.
What conditions does trial NCT00493883 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular, Liver Neoplasms.
What interventions are being tested in trial NCT00493883?
The interventions under investigation include: yttrium Y 90 microspheres (TheraSphere®) (DEVICE).
Who is sponsoring clinical trial NCT00493883?
This trial is sponsored by Southwestern Regional Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493883 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
COMPLETED · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
-
Sorafenib and TRC105 in Hepatocellular Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.